Evidence method
Level · gp.fundamentals.debt_to_revenue
44.08% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
WST · Mar 31, 2019
WEST PHARMACEUTICAL SERVICES INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000105770-19-000020General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
6.49% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
10.73% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.shares_outstanding
-0.13% · CORE · VALID
Evidence method
Yoy · gp.fundamentals.revenue
6.69% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
50.98% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
33.10% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
15.94% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
2.21% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
1.40% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History39 statesSelf-history eligible
Mar 31, 201910/10 normalizedLevel 3Jun 30, 201910/10 normalizedLevel 3Sep 30, 201910/10 normalizedLevel 3Dec 31, 20198/8 normalizedLevel 3Mar 31, 20209/9 normalizedLevel 3Jun 30, 20209/9 normalizedLevel 3Sep 30, 20209/9 normalizedLevel 3Dec 31, 20209/9 normalizedLevel 3Mar 31, 20219/9 normalizedLevel 3Jun 30, 20219/9 normalizedLevel 3Sep 30, 20219/9 normalizedLevel 3Dec 31, 20219/9 normalizedLevel 3Mar 31, 20229/9 normalizedLevel 3Jun 30, 20229/9 normalizedLevel 3Sep 30, 20229/9 normalizedLevel 3Dec 31, 20229/9 normalizedLevel 3Mar 31, 20239/9 normalizedLevel 3Jun 30, 20239/9 normalizedLevel 3Sep 30, 20239/9 normalizedLevel 3Sep 30, 20269/9 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 11.42%
- Current
- 44.08%
- Delta
- 32.66%
- Previous
- 6.10%
- Current
- 6.49%
- Delta
- 0.40%
- Previous
- 16.80%
- Current
- 10.73%
- Delta
- -6.07%
- Previous
- 7.40%
- Current
- 6.69%
- Delta
- -0.71%
- Previous
- 12.49%
- Current
- 50.98%
- Delta
- 38.49%
- Previous
- 31.76%
- Current
- 33.10%
- Delta
- 1.34%
- Previous
- 13.99%
- Current
- 15.94%
- Delta
- 1.95%
- Previous
- 2.35%
- Current
- 2.21%
- Delta
- -0.14%
- Previous
- 0.88%
- Current
- 1.40%
- Delta
- 0.52%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · WST Fundamental State →Has State · WEST PHARMACEUTICAL SERVICES INC →Transitioned To · WST Fundamental State →Transitioned To · WST BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · WST CAPEX_INTENSITY_INCREASED →Transitioned To · WST CASH_GENERATION_DECREASED →Transitioned To · WST GROWTH_DECREASED →Transitioned To · WST INVENTORY_PRESSURE_INCREASED →Transitioned To · WST MARGIN_INCREASED →Transitioned To · WST PROFITABILITY_INCREASED →Transitioned To · WST R_AND_D_INTENSITY_DECREASED →Transitioned To · WST SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.